1. Home
  2. NGL vs OMER Comparison

NGL vs OMER Comparison

Compare NGL & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NGL ENERGY PARTNERS LP

NGL

NGL ENERGY PARTNERS LP

HOLD

Current Price

$12.09

Market Cap

751.7M

Sector

Utilities

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.35

Market Cap

894.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGL
OMER
Founded
1940
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
751.7M
894.8M
IPO Year
2011
2009

Fundamental Metrics

Financial Performance
Metric
NGL
OMER
Price
$12.09
$11.35
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
505.4K
2.4M
Earning Date
02-03-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$1,161,150,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$355.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.64
$2.95
52 Week High
$13.00
$17.65

Technical Indicators

Market Signals
Indicator
NGL
OMER
Relative Strength Index (RSI) 71.60 44.44
Support Level $10.11 $11.44
Resistance Level $13.00 $12.18
Average True Range (ATR) 0.65 0.66
MACD 0.18 -0.19
Stochastic Oscillator 75.36 6.75

Price Performance

Historical Comparison
NGL
OMER

About NGL NGL ENERGY PARTNERS LP

NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: